Axcella Health Inc

Axcella Health — Technical Presentation (September 2022)

62 slides from Axcella Health's technical presentation, Sep 29, 2022

  1. Slide 1: AXA1125-101 Interim Analysis

    © 2022 Axcella Therapeutics. All rights reserved. NASDAQ: AXLA AXA1125 - 101 Interim Analysis September 29, 2022

  2. Slide 2: Forward-Looking Statements

    © 2022 Axcella Therapeutics. All rights reserved. 2 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, including, without limitation, statements regarding the characteristics, c

  3. Slide 3: Today's Agenda

    © 2022 Axcella Therapeutics. All rights reserved. 3 Today’s Agenda Agenda Length Time Speakers Introductory Remarks 10 min 8:00 am – 8:10 am Bill Hinshaw Clinical Trial Design & Results 20 min 8:10 am – 8:30 am Margaret Koziel Mechanism of AXA 1125 10 min 8:30 am – 8:40 am Karim Azer Clinical Releva

  4. Slide 4: Multi-Targeted Therapeutics to Restore Homeostasis

    © 2022 Axcella Therapeutics. All rights reserved. 4 IEM = Inborn Errors of Metabolism Multi - Targeted Therapeutics to Restore Homeostasis Leveraging Endogenous Metabolic Modulator (EMM) compositions to treat complex medical conditions • Complex conditions are driven by dysregulation in , limiting t

  5. Slide 5: World leader of multi-targeted therapies in complex diseases

    © 2022 Axcella Therapeutics. All rights reserved. 5 World leader of multi - targeted therapies in complex diseases Endogenous Metabolic Modulators (EMMs) AXA1125 Long COVID Non - Alcoholic Steatohepatitis (NASH)

  6. Slide 6: NASH is a Complex Disease, Affecting Millions

    © 2022 Axcella Therapeutics. All rights reserved. 6 1. Global Liver Institute U.S. NASH Action Plan (Dec. 2020). 2. Cusi K. Diabetologia . 2016;59:1112 - 20. 3. Company estimates based on Decision Resources Group (DRG). Non - alcoholic Steatohepatitis Landscape & Forecast. DRG. NASH is a Complex Dis

  7. Slide 7: AXA1125 Has Demonstrated Positive Data Across Multiple Trials

    © 2022 Axcella Therapeutics. All rights reserved. 7 F2/F3= stages of NASH fibrosis; NAFLD= non - alcoholic fatty disease; N=number of subjects; T2DM=type 2 diabetes mellitus; wk =weeks AXA1125 Has Demonstrated Positive Data Across Multiple Trials AXA1125 has been studied in 4 clinical trials between

  8. Slide 8: AXA1125-101 Key Results of Interim Analysis

    © 2022 Axcella Therapeutics. All rights reserved. 8 1. Harrison SA, et al. Am J Gastroenterol . 2021:116;2399 - 2409. AXA1125 - 101 Key Results of Interim Analysis AXA1125 continues to demonstrate real biological impact and effect in NASH subjects Significant Improvement in Liver Stiffness at 24 wee

  9. Slide 9: AXA1125: A Differentiated Product with a Potential Frontline Profile

    © 2022 Axcella Therapeutics. All rights reserved. 9 MoA = mechanism of action. AXA1125: A Differentiated Product with a Potential Frontline Profile Multi - Targeted MOA Efficacy Safety / Tolerability Dosing Differentiation Elements Supporting a Frontline Profile: Potential Additional AXA1125 Differe

  10. Slide 10: Clinical Trial Design & Results

    © 2022 Axcella Therapeutics. All rights reserved. 10 Clinical Trial Design & Results Dr. Margaret Koziel Chief Medical Officer

  11. Slide 11: Phase 2b Clinical Trial Underway

    © 2022 Axcella Therapeutics. All rights reserved. 11 D1: Biopsy Fibroscan MRI - PDFF W48: Biopsy Fibroscan MRI - PDFF W24: Fibroscan MRI - PDFF W12: Fibroscan MRI - PDFF ALT=alanine aminotransferase; BID=twice a day; D=day; IA=interim analysis; MRI - PDFF=magnetic resonance imaging of the hepatis pr

  12. Slide 12: Subject Flow and Data Analysis

    © 2022 Axcella Therapeutics. All rights reserved. 12 BID=twice a day; AE=adverse events; N=Number of Subjects Subject Flow and Data Analysis • 123 subjects randomized and received at least one dose • 82 subjects completed the study through week 12 • 58 subjects completed the study through week 24 •

  13. Slide 13: Patient Demographics and Baseline Metrics

    © 2022 Axcella Therapeutics. All rights reserved. 13 Patient Demographics and Baseline Metrics Baseline Demographic/Metric Placebo (N=39) AXA1125 22.6 BID (N=42) AXA1125 33.9 BID (N=42) Mean age in years (SD) 57.8 (9.8) 55.8 (13.5) 56.2 (12.4) Sex Male, n (%) 12 (30.8) 10 (23.8) 19 (45.2) Female, n

  14. Slide 14: Effects on Non-Invasive Measures

    © 2022 Axcella Therapeutics. All rights reserved. 14 Effects on Non - Invasive Measures

  15. Slide 15: Significant Improvements in Liver Stiffness as Measured by FibroScan

    © 2022 Axcella Therapeutics. All rights reserved. 15 *p<0.05, **p<0.01, ***p<0.001, versus placebo; P values derived using mixed models approach. BID=twice a day; LSM=liver stiff nes s measurement; kPa=kilo pascals; SE=standard error; N=Number of Subjects Significant Improvements in Liver Stiffness

  16. Slide 16: Blood Biomarkers Provide Further Evidence of Effect on Fibrosis

    © 2022 Axcella Therapeutics. All rights reserved. 16 *p<0.05, **p<0.01, ***p<0.001, versus placebo; p values derived using mixed models approach. BID=twice daily; N=Number of Sub jec ts; SE=standard error Blood Biomarkers Provide Further Evidence of Effect on Fibrosis Statistically significant chang

  17. Slide 17: Improvements in ALT (Relative Change)

    © 2022 Axcella Therapeutics. All rights reserved. 17 Week 12 Week 24 9.6 - 12.6 * - 21.2 ** -30 -20 -10 0 10 20 mean (SE), % *p<0.05, **p<0.01, ***p<0.001, versus placebo ; p values derived using mixed models approach. BID=twice daily; LSM=liver stif fne ss measurement; kPa=kilo pascals; SE=standard

  18. Slide 18: MRI-PDFF Relative Change from Baseline

    © 2022 Axcella Therapeutics. All rights reserved. 18 Week 12 Week 24 - 6.9 - 14.0 - 11.3 -25 -20 -15 -10 -5 0 5 Relative change, mean (SE), % N = the number of subjects of each treatment arm in the specified category at each visit *p<0.05, **p<0.01, ***p<0.001, versus placebo ; p values derived usin

  19. Slide 19: Proportion Achieving Benchmark Criteria at Week 12

    © 2022 Axcella Therapeutics. All rights reserved. 19 17.2 20.7 39.1 0 10 20 30 40 50 Percent n = the number of subjects who met criteria; N= the number of subjects with a post baseline visit P values using Cochran - Mantel Haenszel test vs placebo *, p< 0.05. 1. Loomba R., et al. Hepatology . 2020;7

  20. Slide 20: Safety

    © 2022 Axcella Therapeutics. All rights reserved. 20 Safety

  21. Slide 21: Safety and Tolerability Remains Favorable Based on the Blinded Review

    © 2022 Axcella Therapeutics. All rights reserved. 21 Safety based on what subject received on day 1 of dosing. DMC, independent data monitoring committee; SAE, serious adverse ev ent ; TEAEs, treatment emergent adverse events Safety Interim Analysis Safety and Tolerability Remains Favorable Based on

  22. Slide 22: Summary of Results From this Interim Analysis

    © 2022 Axcella Therapeutics. All rights reserved. 22 Summary of Results From this Interim Analysis • Significant effects on liver stiffness comparable to or better than other agents in ph2b/3 • Continued demonstration of effects on relevant pathways of NASH biology • Observed safety and tolerability

  23. Slide 23: AXA1125 Mechanism of Action

    © 2022 Axcella Therapeutics. All rights reserved. 23 AXA1125 Mechanism of Action Karim Azer, PhD VP of Platform and Discovery

  24. Slide 24: NASH is a Complex Disease with Pleiotropic Disease Pathways

    © 2022 Axcella Therapeutics. All rights reserved. 24 LIVRQNac (AXA1125) NASH is a Complex Disease with Pleiotropic Disease Pathways AXA1125 is Multi - Targeted by Design Against Key Pathways across NASH Disease Drivers Fibrosis Inflammation Metabolism AXA1125 PPAR α AMPK Urea cycle AA Metabolism AXA

  25. Slide 25: AXA1125 is Multi-Targeted by Design Against Key NASH Pathways

    © 2022 Axcella Therapeutics. All rights reserved. 25 All studies conducted with LIVRQNac , a nonclinical form of AXA1125 containing the constituents of AXA1125: L, I, V, R, Q, Nac added at specified - fold concentrations above plasma (ex: 7.5 × , 15 × , 30 × ), where 1 × concentration matches the me

  26. Slide 26: AXA1125 Improves Key Mitochondrial, Lipid and Energy Pathways

    © 2022 Axcella Therapeutics. All rights reserved. 26 1. Russell et al. EASL ILC2022 and EASL NAFLD Summit . 2022. Primary Human Hepatocytes were co - treated with 83uM:167uM palmitate:oleate and 1 ng/ml TNF - α to simulate conditions in NASH, and were exposed to the same conditions containing 83uM [

  27. Slide 27: AXA1125 Upregulates Fat Oxidation Genes and Pathway

    © 2022 Axcella Therapeutics. All rights reserved. 27 Data derived Primary Human Hepatocyte (PHH) Lipotoxicity Model Primary Human Hepatocytes were co - treated for 48 hours with 167uM:333uM palmitate:oleate and 1 ng/ml TNF - α to simulate conditions in NASH, 30x LIVRQNac , RNA was collected in tripl

  28. Slide 28: AXA1125 Decreases Hepatocyte Damage and Promotes Immune Recruitment

    © 2022 Axcella Therapeutics. All rights reserved. 28 AXA1125 Decreases Hepatocyte Damage and Promotes Immune Recruitment AXA1125 Decreases Hepatocyte Damage and Immune Cell Recruitment and Decreases Proinflammatory Cytokines Multi - targeted impact on inflammation: Decreased Damage, Recruitment, Cyt

  29. Slide 29: AXA1125 Decreases Fibrosis Activation, Proliferation, and Collagen Deposition

    © 2022 Axcella Therapeutics. All rights reserved. 29 Decreases in Collagen Deposition Measured with AXA1125 Reduced Fibrogenic Activation & Proliferation 1. Daou et al. Nat Sci Rep. 2021. ***p < 0.001 versus TGF - β 1, Data from Primary Human Hepatic Stellate Cells pre - treated with LIVRQNac for 24

  30. Slide 30: Key MOA Takeaways

    © 2022 Axcella Therapeutics. All rights reserved. 30 Key MOA Takeaways • NASH is a complex disease with metabolic, inflammatory and fibrotic dysregulations • Combination therapy increases potential to impact multiple targets implicated in NASH • AXA1125 is designed as a multi - targeted agent agains

  31. Slide 31: AXA1125 and NASH Treatment Landscape

    AXA1125 AND NASH TREATMENT LANDSCAPE STEPHEN A. HARRISON, MD, COL (RET.), FAASLD VISITING PROFESSOR OF HEPATOLOGY RADCLIFFE DEPARTMENT OF MEDICINE, UNIVERSITY OF OXFORD MEDICAL DIRECTOR, PINNACLE CLINICAL RESEARCH PRESIDENT, SUMMIT CLINICAL RESEARCH 31

  32. Slide 32: Prevalence of NAFLD Around the World

    PREVALENCE OF NAFLD AROUND THE WORLD Younossi Z, et al. Hepatology. 2019;69(6):2672 - 2682; Younossi ZM et al. J Hepatol. 2019;70(3):531 - 544. 0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0-9 10-19 20-44 45-64 65+ NAFLD prevalence Age (years) Males Females …is increasing in line with obesity , type

  33. Slide 33: Prevalence of NASH Among US Middle-Aged Cohorts

    PREVALENCE OF NASH AMONG US MIDDLE - AGED COHORTS 2 prospective NASH prevalence studies NASH, non - alcoholic steatohepatitis. 1. Williams CD, et al. Gastroenterology . 2011;140:124 – 31; 2. Harrison SA, et al. J Hepatol. 2021;S0168 - 8278:00176 - 8. 119% Increase in < 10 years

  34. Slide 34: NAFLD and NASH Prevalence in Different Groups

    BMI measured in kg/m2 BMI, body mass index; NAFLD; non - alcoholic fatty liver disease; NASH, non - alcoholic steatohepatitis. Harrison SA et al. J Hepatol . 2021;S0168 - 8278:00176 - 8. NAFLD AND NASH PREVALENCE IN DIFFERENT GROUPS (US MIDDLE - AGED COHORT, N=664)

  35. Slide 35: NASH: Potential Therapeutic Targets

    NASH: POTENTIAL THERAPEUTIC TARGETS See slides notes for abbreviations. Adapted from: Konerman MA, et al. J Hepatol. 2018;68:362 – 375. Lipogenesis FFA Collagen deposition ER Stress UPR JNK ROS Hepatic stellate cell activation Kupffer cell SREPB - 1 DNL VLDL SHP FXR/TGR5 Bile acids LPS Immune cell t

  36. Slide 36: The Risk/Benefit Equation Changes as NASH Progresses

    THE RISK/BENEFIT EQUATION CHANGES AS NASH PROGRESSES Safety First Risk Tolerance Liver Disease Progression F0 F1 F2 F3 F4 Agent needed to reduce liver fat and inflammation Safety and tolerability are paramount as agent will likely be used chronically Oral agents strongly preferred Need to bring pati

  37. Slide 37: Multiple Options to Address a Heterogeneous Population

    MULTIPLE OPTIONS TO ADDRESS A HETEROGENEOUS POPULATION NASH’s complex pathophysiology demands development of a vast array of mechanisms and candidates Multi - Targeted Anti - Hyperglycemics Anti - Fibrotic Anti - Hyperlipidemics Anti - Inflammatory Other Candidates in Ph2/3 Development • Belapectin

  38. Slide 38: Phase 2b Clinical Trial Underway

    PHASE 2B CLINICAL TRIAL UNDERWAY PREPLANNED INTERIM ANALYSIS WHEN 30 SUBJECTS/ARM REACHED WEEK 12 D1: Biopsy Fibroscan MRI - PDFF W48: Biopsy Fibroscan MRI - PDFF W24: Fibroscan MRI - PDFF W12: Fibroscan MRI - PDFF Screening 1:1:1 Randomization (N=~270) 8 WEEKS AXA1125 22.6g BID (45.2 g/d) (n=~90) M

  39. Slide 39: Patient Demographics and Baseline Metrics

    PATIENT DEMOGRAPHICS AND BASELINE METRICS Baseline Demographic/Metric Placebo (N=39) AXA1125 22.6 BID (N=42) AXA1125 33.9 BID (N=42) Mean age in years (SD) 57.8 (9.8) 55.8 (13.5) 56.2 (12.4) Sex Male (%) 12 (30.8) 10 (23.8) 19 (45.2) Female (%) 27 (69.2) 32 (76.2) 23 (54.8) Mean Body Mass Index (kg/

  40. Slide 40: Effects on Non-Invasive Measures

    EFFECTS ON NON - INVASIVE MEASURES

  41. Slide 41: Different Context of Use for NITs

    Diagnosis of at risk NASH Monitoring Response to Therapeutic Interventions Predicting Long - Term Outcomes DIFFERENT CONTEXT OF USE FOR NIT s

  42. Slide 42: Different Context of Use for NITs: Monitoring Response

    Monitoring Response to Therapeutic Interventions DIFFERENT CONTEXT OF USE FOR NIT s

  43. Slide 43: Significant Improvements in Liver Stiffness

    SIGNIFICANT IMPROVEMENTS IN LIVER STIFFNESS CONSISTENT WITH PRIOR DATA ON FIBROSIS MARKERS AT WEEK 16 *p<0.05, **p<0.01, ***p<0.001, versus placebo; P values derived using mixed models approach. LSM, liver stiffness measurement ; k Pa, kilo pascals; SE, standard error Week 12 Week 24 All Subjects 0.

  44. Slide 44: AXA1125 Effects on Liver Stiffness Comparable to Other Best in Class Agents

    AXA1125 EFFECTS ON LIVER STIFFNESS IN COMPARABLE TO OTHER BEST IN CLASS AGENTS IN LATE DEVELOPMENT 1 Yale,C. (September 13, 2022). Phase 2b HARMONY Study Results [PowerPoint presentation]. Akero Phase 2B HARMONY Trial Data Presentation. https:// ir.akerotx.com /static - files/b3cbfed1 - 3eee - 49cf

  45. Slide 45: Blood Biomarkers Provide Further Evidence of Effect on Fibrosis

    BLOOD BIOMARKERS PROVIDE FURTHER EVIDENCE OF EFFECT ON FIBROSIS STATISTICALLY SIGNIFICANT CHANGES SEEN AS EARLY AS WEEK 12 *p<0.05, **p<0.01, ***p<0.001, versus placebo; p values derived using mixed models approach. SE, standard error FIB - 4 Score (Week 24) ELF Score (Week 24) 0.4 - 0.3 ** - 0.3 **

  46. Slide 46: ELF Monitoring Response: REGENERATE Evidence

    ELF Monitoring Response to Therapeutic Interventions EVIDENCE FROM REGENERATE TRIAL 18 - MONTH INTERIM ANALYSIS – OBETICHOLIC ACID N=931 • Patients with >1 - stage fibrosis improvement had the greatest improvement in NITs, while patients with > 1 - stage fibrosis worsening typically showed no NIT impr

  47. Slide 47: FIB-4 Monitoring Response: REGENERATE Evidence

    FIB - 4 Monitoring Response to Therapeutic Interventions EVIDENCE FROM REGENERATE TRIAL 18 - MONTH INTERIM ANALYSIS – OBETICHOLIC ACID N=931 • Patients with >1 - stage fibrosis improvement had the greatest improvement in NITs, while patients with > 1 - stage fibrosis worsening typically showed no NIT

  48. Slide 48: Proportion Achieving Benchmark Criteria at Week 12

    17.2 20.7 39.1 0 10 20 30 40 50 Percent PROPORTION ACHIEVING BENCHMARK CRITERIA AT WEEK 12 n = the number of subjects who met criteria; N= the number of subjects with a post baseline visit; P values using Cochran - Mante l Haenszel test vs placebo 11.1 35.7 28.6 0 5 10 15 20 25 30 35 40 Percent p=0.

  49. Slide 49: AXA1125 Demonstrated Similar Results in a Prior NASH Clinical Study

    AXA1125 DEMONSTRATED SIMILAR RESULTS IN A PRIOR NASH CLINICAL STUDY Harrison SA, Baum SJ, Gunn NT, Younes ZH, Kohli A, Patil R, Koziel MJ, Chera H, Zhao J, Chakravarthy MV. Safety, Tolerability , a nd Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease. Am J Ga

  50. Slide 50: ALT Monitoring Response: FLINT Trial Evidence

    ALT Monitoring Response to Therapeutic Interventions EVIDENCE FROM FLINT 72 - WEEK TRIAL OBETICHOLIC ACID N=283 17 IU/L ALT decline was significantly associated with histologic markers of response Loomba, Rohit et al. “Factors Associated With Histologic Response in Adult Patients With Nonalcoholic S

  51. Slide 51: ALT Monitoring Response: REGENERATE Evidence

    Rinella ME. Non - invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2022 Mar;76(3):536 - 548 ALT Monitoring Response to Therapeutic Interventions EVIDENCE FROM REGENERATE TRIAL 18 - MONTH INTERIM ANALYSIS – OBETICHOLIC ACID N=931

  52. Slide 52: MRI-PDFF Monitoring Response: Resmetirom Phase 2 Evidence

    MRI - PDFF Monitoring Response to Therapeutic Interventions EVIDENCE FROM RESMETIROM 36 - WEEK PH2 TRIAL MRI Responders: ≥ 30% relative decline in LFC Harrison SA In a placebo - controlled 36 - week phase 2 trial, treatment with MGL - 3196 compared to placebo results in significant reduc - tions in

  53. Slide 53: ≥30% Relative Decline in MRI-PDFF

    Stine JG, Munaganuru . Change in MRI - PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta - Analysis. Clin Gastroenterol Hepatol. 2021 Nov. MRI - PDFF Monitoring Response to Therapeutic Interventions ≥30% RELATIVE DECLINE IN MRI - PDFF Change in

  54. Slide 54: Safety

    SAFETY

  55. Slide 55: Safety and Tolerability Remains Favorable Based on the Blinded Review

    Safety based on what subject received on day 1 of dosing. DMC, independent data monitoring committee; SAE, serious adverse ev ent ; TEAEs, treatment emergent adverse events • Most frequent TEAEs are gastrointestinal • All SAEs and the death unrelated to study product • No safety or tolerability sign

  56. Slide 56: Summary

    SUMMARY The current study is enrolling patients with significant NASH and fibrosis AXA1125 appears safe and well tolerated Oral formulation is key benefit Non - invasive tests obtained at a relatively short time period in a subset of patients enrolled suggest a positive impact on disease activity an

  57. Slide 57: Closing Remarks

    © 2022 Axcella Therapeutics. All rights reserved. 57 Closing Remarks Bill Hinshaw Chief Executive Officer

  58. Slide 58: AXA1125 Effects on Liver Stiffness Comparable to Other Best in Class Agents

    © 2022 Axcella Therapeutics. All rights reserved. 58 0.13 - 0.7 1.06 1.09 - 2.01 - 2.6 0.76 - 0.58 - 4.07 - 4.3 - 1.32 -5.0 -4.0 -3.0 -2.0 -1.0 0.0 1.0 2.0 AXA1125 24 wk EFX 24 wk SEM 72 wk OCA 72 wk Absolute change in LSM (kPa) AXA1125 effects on liver stiffness are comparable to other best in clas

  59. Slide 59: Conclusion

    © 2022 Axcella Therapeutics. All rights reserved. 59 1 Global Liver Institute U.S. NASH Action Plan (Dec. 2020) Image sourced from: https://www.today.com/health/nonalcoholic - fatty - liver - disease - are - you - risk - t121855 Conclusion • NASH is a large complex disease with a high unmet need and

  60. Slide 60: Milestone Rich Time

    © 2022 Axcella Therapeutics. All rights reserved. 60 Milestone timing based on current expectations and subject to change. Milestone Rich Time Program Update Timing AXA1125 for NASH Phase 2b Interim Data Q3 2022 x First Adolescent Subject Enrolled Q4 2022 Scientific Communication 2H 2022 NASH Top -

  61. Slide 61: Q&A

    © 2022 Axcella Therapeutics. All rights reserved. 61 Q&A Bob Crane Chief Financial Officer, Axcella Dr. Margaret Koziel Chief Medical Officer, Axcella Bill Hinshaw President & Chief Executive Officer Axcella Dr. Karim Azer Head of Platform and Discovery, Axcella Dr. Stephen Harrison Medical Director

  62. Slide 62: Thank You

    © 2022 Axcella Therapeutics. All rights reserved. NASDAQ: AXLA 840 Memorial Drive, Third Floor Cambridge, MA 02139 www.axcellatx.com Thank You

Axcella Health — Technical Presentation (September 2022) on 6ix